Some new approaches to potential test systems for drugs against prostatic cancer.
We have previously reported on test systems, based on 5alpha-reductase (5alpha-RA) and arginase activities and steroid deposition in animal prostates, potentially useful in screening drugs possibly effective in cancer of the prostate. Recently, we have concentrated on the development of other in vivo and in vitro systems which may prove of further value in testing such drugs. These systems include the following: (a) The effects of drugs on 5alpha-RA activity in human and animal non-malignant and human cancerous prostatic tissues in organ culture. The parameters necessary for the maintenance of optimal 5alpha-RA in such explants have been determined, and it has been shown that certain agents (estramustine phosphate, progesterone, estradiol-17beta) can inhibit 5alpha-RA under in vitro conditions, pointing to the potential use of such an approach in screening various cytostatic agents. In addition, 65Zn deposition, the histology, and the androgen metabolism in such tissues in organ culture are being determined as additional parameters. (b) The deposition of 65Zn in the rat dorsolateral gland, particularly as affected by prolactin and testosterone, and the effects of chemotherapeutic agents on such deposition. Methotrexate and CCNU have been shown to be potent inhibitors of 65Zn deposition in the dorsolateral gland. The parameters related to zinc metabolism in the prostate are being further investigated. (c) The demonstration of receptors for estrogens (estradiol-17beta, diethylstilbestrol) in the prostate of the baboon. The various parameters related to the specificity of such receptors have been established. The development and standardization of these approaches, some facets of which are reported in the present publication, may prove them to be more sensitive, specific, and optimal than other systems and should afford an opportunity to test various combinations of drugs potentially useful in cancer of the prostate with relative speed, efficacy, and ease of manipulation.
D000315:Adrenalectomy; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002369:Castration; D003534:Cyproterone / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D004958:Estradiol / Q000494:pharmacology; D004967:Estrogens / Q000378:metabolism; D000882:Haplorhini; D008297:Male; D009924:Organ Culture Techniques; D010088:Oxidoreductases / Q000378:metabolism; D010215:Papio; D011374:Progesterone / Q000494:pharmacology; D011389:Prolactin Release-Inhibiting Factors / Q000494:pharmacology; D011467:Prostate / Q000201:enzymology / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D051381:Rats; D013739:Testosterone / Q000494:pharmacology; D015032:Zinc / Q000378:metabolism
D000970:Antineoplastic Agents; D004967:Estrogens; D013739:Testosterone; D011374:Progesterone; D004958:Estradiol; D011389:Prolactin Release-Inhibiting Factors; D003534:Cyproterone; D010088:Oxidoreductases; D015032:Zinc